Shumao Ni
Research Subjects
Shumao Ni has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Frank Wu
TransThera Sciences (Nanjing), Inc., Nanjing, China
61 shared publications - Peng Peng
TransThera Sciences (Nanjing), Inc., Nanjing, China
61 shared publications - Chao Hu
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China
36 shared publications - Di Wu
Department of Medicinal Chemistry, Pharmacology, Project Management, Drug Metabolism and Pharmacokinetics, TransThera Sciences (Nanjing), Inc., Nanjing, Jiangsu, P.R. China
36 shared publications - Dong Wang
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
36 shared publications - Elisabetta Marangoni
Translational Research Department, Institut Curie
36 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Pharmacokinetic Parameters of Doses at Cycle 1 Day 28 in Arm C.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Pharmacokinetic Parameters of Doses at Cycle 1 Day 28 in Arm C.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Frequency of selected genomic alterations and PFS in TNBC and aTNBC.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Frequency of selected genomic alterations and PFS in TNBC and aTNBC.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Overview of baseline mutations among patients with breast cancer (A), selected mutations in responders versus nonresponders (B), and relative change in VAF from baseline to cycle 3 days 1 (C).
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Overview of baseline mutations among patients with breast cancer (A), selected mutations in responders versus nonresponders (B), and relative change in VAF from baseline to cycle 3 days 1 (C).
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Inclusion and Exclusion Criteria.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Inclusion and Exclusion Criteria.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Time to PFS According to RECIST 1.1.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Time to PFS According to RECIST 1.1.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S12 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Hypertension Management Guidelines.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S12 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Hypertension Management Guidelines.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Gene List for the FoundationOne Liquid CDx Assay.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Gene List for the FoundationOne Liquid CDx Assay.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Fleming’s Two-Stage Design for Enrollment of Each Preferred Indication.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Fleming’s Two-Stage Design for Enrollment of Each Preferred Indication.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Prior Lines of Therapies for Cholangiocarcinoma, Breast Cancer, and Prostate Cancer Populations as well as Total Population (A) and Baseline FGFR Status (B).
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Prior Lines of Therapies for Cholangiocarcinoma, Breast Cancer, and Prostate Cancer Populations as well as Total Population (A) and Baseline FGFR Status (B).
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Representativeness of Study Participants.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Representativeness of Study Participants.